The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Open accessAbstract
In vitro susceptibilities of 36 zygomycete isolates, belonging to six genera, to itraconazole, posaconazole, voriconazole, terbinafine, amphotericin B and 5-fluorocytosine were determined by using a broth microdilution adaptation of the National Committee for Clinical Laboratory Standards M-38P reference method. The influence of incubation time on MIC values, and the performance of a spectrophotometric method for MIC determination in comparison with the visual reference method, were also evaluated. Amphotericin B was active against most of the isolates. All the isolates were highly resistant to 5-fluorocytosine (MICs > 256 mg/L). Voriconazole was significantly less active than the other drugs with an overall MIC(90) (MIC at which 90% of the isolates were inhibited) of 32 mg/L. In contrast, posaconazole showed good activity (MIC(90) 1 mg/L). A wide range of MICs, from 0.03 to > or =32 mg/L, was obtained for itraconazole and terbinafine. Differences in susceptibility between and within genera were noted. Rhizopus spp. were significantly less susceptible to itraconazole, posaconazole, terbinafine and amphotericin B than Absidia spp., and less susceptible than Mucor spp. to amphotericin B. Terbinafine appeared to be more active against Rhizopus microsporus than against Rhizopus oryzae (geometric mean MIC of 0.15 and 64 mg/L, respectively). The activity of the drugs was dependent on the incubation period. A significant increase in MICs was noted between 24 and 48 h of incubation. On the other hand, the two methods used for MIC determination (visual and spectrophotometric readings) showed good agreement. These results suggest that the zygomycetes are a heterogeneous group for antifungal susceptibility. Some of the conventional and new antifungals are effective in vitro; their efficacies in vivo remain to be determined. The spectrophotometric method appears to be a valuable alternative to the visual method for MIC determination for zygomycetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.198-202.1998 · Cited by 361
Espinel-Ingroff, A., Dawson, K., Pfaller, M., Anaissie, E., Breslin, B., Dixon, D., Fothergill, A., Paetznick, V, Peter, J., & Rinaldi, M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.2.314 · Cited by 245
Analysis of Growth Characteristics of Filamentous Fungi in Different Nutrient Media
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., & Verweij, P. E. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.2.478-484.2001 · Cited by 241
Pfaller, M. A., Marco, F., Messer, S. A., & Jones, R. N. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00246-0 · Cited by 241
Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A., McGinnis, M. R., Menezes, P., Messer, S. A., Nelson, P. W., et al. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.1.139-143.1997 · Cited by 228
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
Johnson, E. M., Szekely, A., & Warnock, D. W. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.741 · Cited by 215
Cited by
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Self-citationSkiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., Lass-Florl, C., Bouza, E., Klimko, N., Gaustad, P., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03456.x · Cited by 748
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Kontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G., Healy, M., Perego, C., Safdar, A., Kantarjian, H., Champlin, R., Walsh, T. J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428780 · Cited by 674
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Posaconazole as Salvage Therapy for Zygomycosis
Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.126-133.2006 · Cited by 555
Recent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491
Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species
Gomes, M. Z. R., Lewis, R. E., & Kontoyiannis, D. P. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-10 · Cited by 443
Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole
Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A., & Marr, K. A. (2004) · Clinical Infectious Diseases · doi:10.1086/423274 · Cited by 402
Skiada, A., Lanternier, F., Groll, A. H., Pagano, L., Zimmerli, S., Herbrecht, R., Lortholary, O., Petrikkos, G. L., & Leukemia*, O. B. O. T. T. E. C. O. I. I. (2013) · Haematologica · doi:10.3324/haematol.2012.065110 · Cited by 372
Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3623-3626.2003 · Cited by 371
Zygomycosis: the re-emerging fungal infection
Chayakulkeeree, M., Ghannoum, M. A., & Perfect, J. R. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0107-1 · Cited by 368
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Balajee, S. A., Borman, A. M., Brandt, M. E., Cano, J., Cuenca-Estrella, M., Dannaoui, E., Guarro, J., Haase, G., Kibbler, C. C., Meyer, W., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01685-08 · Cited by 326
Self-citationNewer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Siwek, G. T., Dodgson, K. J., de Margarida, M.-S., Bartelt, L. A., Kilborn, S. B., Hoth, P. L., Diekema, D. J., & Pfaller, M. A. (2004) · Clinical Infectious Diseases · doi:10.1086/422723 · Cited by 293
Posaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., & Kusne, S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00452-07 · Cited by 285
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Invasive Zygomycosis: Update on Pathogenesis, Clinical Manifestations, and Management
Kontoyiannis, D. P., & Lewis, R. E. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.003 · Cited by 261
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
Greenberg, R. N., Scott, L. J., Vaughn, H. H., & Ribes, J. A. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200412000-00003 · Cited by 258
Synthesis, Self-Assembly, and Biomedical Applications of Antimicrobial Peptide–Polymer Conjugates
Sun, H., Hong, Y., Xi, Y., Zou, Y., Gao, J., & Du, J. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00208 · Cited by 253
Espinel-Ingroff, A., Arthington-Skaggs, B., Iqbal, N., Ellis, D., Pfaller, M. A., Messer, S., Rinaldi, M., Fothergill, A., Gibbs, D. L., & Wang, A. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00134-07 · Cited by 182
Current status of antifungal susceptibility testing methods
Arikan, S. (2007) · Medical Mycology · doi:10.1080/13693780701436794 · Cited by 152
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.96-103.2006 · Cited by 121
Management of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100
Antifungal combinations in Mucorales: A microbiological perspective
Schwarz, P., Cornely, O. A., & Dannaoui, E. (2019) · Mycoses · doi:10.1111/myc.12909 · Cited by 43
Self-citation
Metadata
- Authors
- Dannaoui, E.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-28
- Volume
- 51
- Issue
- 1
- Pages
- 45-52
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2126638225
- Cited by
- 314
- References
- 30
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.